QIAGEN Appoints Jonathan M. Pratt as Chief Executive Officer
Jon Pratt brings more than 25 years of leadership experience, most recently as CEO of Filtration Group and previously at Waters, Beckman Coulter Life Sciences and Pall
To assume CEO role on September 1, 2026, succeeding Thierry Bernard
QIAGEN reaffirms outlook for the third quarter and full-year 2026; strategic review continues
QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that Jonathan M. Pratt has been appointed Chief Executive Officer, effective September 1, 2026. He brings to QIAGEN more than 25 years of international leadership experience across life sciences, laboratory technologies and healthcare.
